T-DM1 Promising as Neoadjuvant Therapy in Early BC

Action Points

  • Substituting trastuzumab emtansine (TDM1), an antibody-drug conjugate of trastuzumab with the cytotoxic compound DM1 (Kadcyla) for trastuzumab (Herceptin) as neoadjuvant therapy resulted in a high rate of pathologic complete response (pCR) without the need for chemotherapy in some patients with early HER2-positive breast cancer.
  • Note that in the safety analysis, the number of patients who suffered at least one grade 3 or greater adverse event was not significantly higher in the pooled T-DM1 treatment arms compared with the trastuzumab + endocrine therapy group.

Substituting an antibody-drug conjugate of trastuzumab with the cytotoxic compound DM1 (T-DM1, Kadcyla) for trastuzumab (Herceptin) as neoadjuvant therapy resulted in a high rate of pathologic complete response (pCR) without the need for chemotherapy in some patients with early HER2-positive breast cancer, researchers reported.

After 12 weeks of therapy, 41% of patients treated with T-DM1, and 41.5% of those treated with T-DM1 plus endocrine therapy (ET), achieved pCR, compared with 15% of those treated with trastuzumab plus ET (P<0.001), said Nadia Harbeck, MD, PhD, of the University of Munich in Germany, and colleagues.

In addition, 40% of patients treated with T-DM1 and 47% of those receiving T-DM1+ET required no additional chemotherapy after surgery, compared with 22% of those treated with trastuzumab+ET, Harbeck’s group reported online in the Journal of Clinical Oncology.

“Low toxicity and high…

Article Source…

Leave a Reply

Your email address will not be published. Required fields are marked *